Sugi Predict

Sugi Predict / Compounds / SCHEMBL979052

SCHEMBL979052

SCHEMBL979052

CC(C)(C)[Si](C)(C)OCc1ccc(C=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 1/20 0.40
▸ ALDH1A1 P00352 5/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ CYP2A6 P11509 2/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ NR1H4 Q96RI1 1/20 0.37
▸ PDCD1 Q15116 1/20 0.37
▸ CD274 Q9NZQ7 1/20 0.37
▸ RAB9A P51151 2/20 0.36
▸ ALDH5A1 P51649 1/20 0.36
▸ ABAT P80404 1/20 0.36
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ TACR2 P21452 1/20 0.35
▸ ALDH1A3 P47895 2/20 0.35
▸ ALDH3A1 P30838 1/20 0.35
▸ MEN1 O00255 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1206221 0.85 RAB9A (0.47) BACE1ALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL7185780 0.84 RAB9A (0.46) BACE1ALDH1A1SMN1; SMN2MAPTCYP2A6
SCHEMBL2356225 0.83 ALDH1A1 (0.41) BACE1ALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL5881932 0.83 BACE1 (0.35) BACE1
SCHEMBL8348643 0.83 ALDH1A1 (0.38) BACE1ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL664372 0.81 ALDH1A1 (0.42) BACE1ALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL4332449 0.81 MAOA (0.47) BACE1ALDH1A1SMN1; SMN2RAB9AMAOA
SCHEMBL15774691 0.80 RAB9A (0.51) BACE1ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL3019114 0.80 BACE1 (0.44) BACE1
SCHEMBL31073116 0.80 BACE1 (0.39) BACE1ALDH1A1SMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024173646-A1 CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-08-22 — — WO disclosed
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 — — US disclosed
US-20220106321-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-04-07 — — US disclosed
US-11279704-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-03-22 — — US disclosed
CN-108440370-B Inhibitors of viral replication 鲁汶天主教大学 2021-07-30 — — CN disclosed
US-20210047361-A1 OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS SILICON VALLEY BANK 2021-02-18 — — US disclosed
WO-2020247782-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF AVIDITY BIOSCIENCES, INC. (US) 2020-12-10 — — WO disclosed
WO-2020206381-A1 CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS AND METHODS OF USING AND MAKING SAME SUTTON LARRY D (US) 2020-10-08 — — WO disclosed
WO-2019145713-A9 OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS EVONETIX LTD (GB) 2020-08-06 — — WO disclosed
EP-3617192-A1 VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2020-03-04 — — EP disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 — — US disclosed
EP-1380562-A1 CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF Eisai Co., Ltd. (JP) 2004-01-14 — — EP disclosed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 — — EP disclosed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 — — WO disclosed
US-5914406-A ENZYME INHIBITOR; USEFUL FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS AND ALOPECIA HOFFMAN-LA ROCHE INC. (US) 1999-06-22 — — US disclosed
US-5750706-A TREATMENT OF INFLAMMATORY SKIN DISORDERS AND ALOPECIA HOFFMANN-LA ROCHE INC. (US) 1998-05-12 — — US disclosed
US-5653914-A Electroluminescent device comprising a chromophoric polymeric composition CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 1997-08-05 — — US disclosed
US-5583222-A ANTIINFLAMMATORY AGENTS FOR TREATMENT OF SKIN DISORDERS HOFFMANN-LA ROCHE INC. (US) 1996-12-10 — — US disclosed
WO-1996010559-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-11 — — WO disclosed
WO-1994015441-A1 ELECTROLUMINESCENT DEVICE COMPRISING A CHROMOPHORIC POLYMERIC COMPOSITION CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 1994-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279704-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 BACE1 2559/4885ALDH1A1 4277/4885SMN1; SMN2 2456/4885
US-20210047361-A1 OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS POLN, POLI, ADAR BACE1 4713/4885ALDH1A1 4015/4885SMN1; SMN2 408/4885
US-20220106321-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 BACE1 2559/4885ALDH1A1 4277/4885SMN1; SMN2 2456/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 BACE1 2559/4885ALDH1A1 4277/4885SMN1; SMN2 2456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.